Charles Magness, PhD
President & Chief Executive Officer
Dr. Magness co-founded Kineta in 2007 and serves as President and Chief Executive Officer. He is responsible for strategy and execution of all corporate initiatives, development opportunities and acquisition of capital. Under his leadership, Kineta has moved rapidly to acquire and finance its lead autoimmune program and advance its discovery stage antiviral research. Dr. Magness secured several significant investment partnerships. As a founder, he also developed and successfully implemented Kineta's business model which is designed to reduce investor risk and provide faster returns on investment.

Dr. Magness, along with Kineta co-founder, Dr. Shawn Iadonato, founded Illumigen Biosciences, Inc. in 2000. Serving initially as CIO and then President and COO from 2002-2007, Dr. Magness led that company from inception to acquisition by Cubist Pharmaceuticals. During his tenure, Illumigen raised over $23M through financing and business development activities, contract revenue, and grants. At Illumigen, he also was responsible for investor relations, intellectual property licensing and legal affairs.

Prior to founding Illumigen, he managed sequence data analysis for the University of Washington Genome Center and co-developed SEGMAP, a widely used tool essential for mapping the human genome. Dr. Magness has more than 25 years experience developing and managing statistical solutions for large scientific projects. He received a Research Career Award from the National Institutes of Health for his transition into human genomics from his formal training in mechanical and aerospace engineering. After earning his B.S., M.S., and Ph.D. degrees from Lehigh University, he was a Research Scientist at McDonnell Douglas Research Labs. He is co-inventor on multiple issued US and international patents and was awarded an official commendation when employed by the US Army.

Shawn Iadonato, PhD
Executive Vice President & Chief Scientific Officer
Dr. Iadonato co-founded Kineta in 2007. He serves as both Executive Vice President and Chief Scientific Officer. In his role as Chief Scientific Officer his principal responsibility is for setting Kineta's research and development priorities. Dr. Iadonato also heads up both the scientific advisory team and the evaluation team responsible for identifying and appraising in-licensing and developmental opportunities. He is principle investigator of Kineta's NIH-funded vaccine adjuvant, antiviral and autoimmune drug development programs.

Dr. Iadonato previously co-founded and served as CSO of Illumigen Biosciences, Inc. There, he pioneered Illumigen's patented drug discovery methodology which relied upon recruitment and screening of healthy populations and elucidation of their shared "wellness" genes. Dr. Iadonato also led the successful discovery and preclinical development of Illumigen's anti-hepatitis C drug, which ultimately led to the sale of the company in December, 2007.

Prior to founding Illumigen, Dr. Iadonato managed the Human Genome Project data collection effort at the University of Washington Genome Center. He has also been central in several other large scientific collaborations and has served on a number of National Institutes of Health scientific review panels. He is co-inventor on more than 35 patents or patent applications.

Dr. Iadonato received a Ph.D. in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.

Blake Ilstrup, JD
General Counsel and Senior Vice President of Corporate Affairs
Mr. Ilstrup manages all legal matters at Kineta, and is a key member of Kineta's corporate development, business development and financing teams. Prior to joining Kineta, Mr. Ilstrup practiced law with Cooley LLP, where he worked with a wide variety of technology and life science companies, venture capital firms and investment banks as outside counsel. He has also served as Vice President and General Counsel of Qpass, a Seattle-based software company, ushering Qpass through its sale to Amdocs (NYSE: DOX). Before his legal career, Mr. Ilstrup served in the United States Navy as a decorated Surface Warfare Officer aboard the guided missile cruiser USS ARKANSAS (CGN 41).

Mr. Ilstrup has been recognized as a "Rising Star" among Washington State lawyers every year since 2003 in the annual survey by Washington Law & Politics magazine. He is also listed in the Best Lawyers in America publication for Venture Capital law. Mr. Ilstrup earned his J.D. from the University of California - Hastings College of the Law, where he was Senior Articles Editor for the Hastings Law Journal and won the American Jurisprudence Award in Negotiation. He received his A.B. in International Relations from Stanford University. Mr. Ilstrup is admitted to practice in Washington and California and is a member of the American Bar Association, the Washington State Bar Association, the State Bar of California, and the King County Bar Association. He is also a member of Leadership Tomorrow, a Seattle organization dedicated to developing effective community leaders, and is on the Board of The Attic Learning Community.

William Cadwallader, MBA
Senior Vice President, Corporate Development
Mr. Cadwallader initiates and leads Kineta's corporate development strategies. He manages the company's business development. While at Kineta Mr. Cadwallader has led negotiation and completion of multiple corporate alliances and product licenses including the worldwide licensing agreement with Airmid, Inc. and the University of California, Irvine for the ShK-Analogs and the strategic alliance with MPI Research. Mr. Cadwallader is a key player in the development the company's corporate financing strategy.

Earlier, Mr. Cadwallader was vice president for product and strategic marketing at Cell Therapeutics, Inc., where his position was integral to the product license and alliance management of Cell Therapeutics' oncology collaboration with pharmaceutical giant, Novartis. Mr. Cadwallader also held numerous positions at Amgen, Thousand Oaks, CA. There, he took on increased responsibilities, holding key positions in strategic planning, marketing, global marketing and product licensing. In addition, he played an essential role in the launch of Neulasta® (pegfilgrastim), now a $3 billion franchise product. Mr. Cadwallader also was part of the successful joint venture of Sankyo and Parke Davis, assisting in the establishment of the U.S. commercial presence of Sankyo Ltd. Mr. Cadwallader began his career as a sales representative for the Upjohn Co., Kalamazoo, Michigan.

Mr. Cadwallader is a graduate of Eastern Washington University and earned his MBA from Seattle University.

Kenneth North
Senior Vice President, Finance
Ken North is senior vice president of finance at Kineta. His primary responsibility is generating financing for Kineta and its array of drug development programs. Mr. North strategically matches Kineta's short and long term goals with those of investors, foundations and institutions. As a member of Kineta's executive team, Ken also contributes to high level financial and strategic planning.

Prior to joining Kineta in 2008, Mr. North spent nearly thirty years leading, and earlier managing several financial institutions. Most recently he served as President and CEO at Seattle Savings Bank. There, Mr. North was responsible for creating the successful business and marketing plans for the bank and greatly enhancing its value by developing unique product lines. He also was instrumental in launching and licensing Seattle Savings Bank at its inception. Before that, he held key leadership positions at Metropolitan Savings Bank and was responsible for managing $90 million in deposits.

Mr. North gives back generously to many important community organizations. He holds leadership roles in the Kiwanis Club of Seattle, Greater Seattle Chamber of Commerce and First Place, an organization that operates a school for homeless children and provides after school athletic programs.

P. Campion Fellin, MSE
Vice President, Operations
Mr. Fellin brings over 20 years of commercial operations and program management experience to Kineta. He was instrumental in the seamless startup of Kineta and oversees Kineta operations and information technology infrastructure. He also has direct responsibility for managing the implementation of business development activities, including finance and budget development.

Prior to Kineta, Mr. Fellin was responsible for overseeing all Bioinformatics development and Information Technology systems at Illumigen Biosciences. In earlier successes, he was responsible for multiple commercial software programs through design, development, and management positions at 360 Powered Corporation, WRQ, and Attachmate Corporation. His products have earned user interface awards from national computing magazines. Mr. Fellin began his career at the Boeing Company where he was responsible for research and development aspects of multiple avionics programs. Campion is a graduate of the University of Michigan Engineering School and earned his master's degree in Software Engineering from Seattle University.

Luke Fouke, M.B.A.
Vice President, Business Development
Mr. Fouke is an eighteen-year veteran of the financial services sector who joined Kineta to develop and enhance our current and future business development initiatives. Mr. Fouke's primary focus is to generate funding from endowments, foundations, institutions and accredited investors.

Prior to joining Kineta, Mr. Fouke worked for Net Lease Holdings, a St. Louis based partnership that provides long-term financing to middle market companies through a sale-leaseback transaction. From 1996 to 2004, Mr. Fouke worked for two boutique investment banks as a Senior Equity Analyst and Institutional Broker: Friedman, Billings, Ramsey & Co., in Washington DC and Seattle-based Delafield Hambrecht, Inc. Earlier, Luke was in the commercial loan division for Southwest Bank of St. Louis. He is a graduate of Denison University and he earned his MBA from Washington University's Olin School of Business.

Meg O'Conor Bannecker
Director of Investor Relations and Corporate Communications
Ms. O'Conor directs investor relations and corporate communications at Kineta. Ms. O'Conor has been a key player in the development of Kineta's outreach effort designed to complement the company's innovative business model. During her time with Kineta, Ms. O'Conor has executed strategies to sharpen corporate messages and to develop new relationships with opinion leaders, investors and the news media. Prior to joining Kineta, Ms. O'Conor directed corporate communications services for Bannecker & Associates Public Affairs, where she designed and executed media and community relations for the company's clients in an array of business sectors from environmental services to advertising, real estate and biotechnology.

Earlier, Ms. O'Conor spent a decade and a half working as a broadcast news reporter and news anchor in a number of television markets. In Seattle, she worked for KSTW, The Ten O'clock News (CBS, UPN) and KING 5 News (NBC). Ms. O'Conor has interviewed a broad array of national and international news makers. She is a graduate of Smith College.

CLINICAL AND SCIENTIFIC ADVISORS

Michael G. Katze, Ph.D. - Scientific Founder
Dr. Katze is Professor of Microbiology at the University of Washington and Associate Director and Core Staff Scientist at the Washington National Primate Research Center. He is also the Program Director for a National Institute on Drug Abuse P30 Center on Functional Genomics and HCV-Associated Liver Disease, Director of a National Institute of Allergy and Infectious Diseases contract focused on using systems biology approaches to study the host response to emerging respiratory virus infections, and Co-Director of the Pacific Northwest Regional Center of Excellence. He has studied virus-host interactions for more than 30 years and is a leader in applying systems biology approaches to the study of virus-host interactions and the interferon response. He is an author of over 200 papers and reviews and received the Milstein Award from the International Society of Interferon and Cytokine Research for his contributions to the interferon field. He was also recently awarded the prestigious Dozor Scholar Award by the Israeli Microbiology Society for his research accomplishments. Dr. Katze heads a laboratory of over 35 individuals that is focused on understanding the complex interplay between viruses and the cells they infect and the mechanisms used by viruses to avoid the innate antiviral response. The lab is at the forefront in using high-throughput technologies and computational methods to study virus infection. These approaches are used to analyze a broad range of experimental systems, including those focused on influenza virus, hepatitis C virus (HCV), Ebola virus, SARS-associated coronavirus, and simian and human immunodeficiency viruses. Dr. Katze was previously a member of the Illumigen Science Advisory Board. He holds a Ph.D. in Microbiology from the Hahnemann Medical College.

Michael Gale, Jr., Ph.D. - Scientific Founder
Dr. Gale serves as a Professor in the Department of Immunology at the University of Washington and is an Adjunct Professor in the U.W. Departments of Global Health and Microbiology. He also is an affiliate member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center. He directs a large molecular virology and viral immunology research program at the University of Washington School of Medicine. Dr. Gale is the Director of the National Institutes of Health (NIH) funded Center for the Study of Immune Mechanisms of Virus Control at the University of Washington, School of Medicine where his research program is focused on understanding the virus-host interactions that regulate innate immunity against RNA viruses. Dr. Gale is also the Director of a newly-established Center for the Study of Hepatitis C Virus Infection and Immunity, part of a national network of Hepatitis C Cooperative Research Centers funded by the NIH. His laboratory is a component of the Pacific Northwest Research Center of Excellence in Biodefense and Emerging Infectious Diseases, where he leads a research program to define therapeutic targets to control pathogenic flavivirus infection. Dr. Gale teaches virology, immunology, infectious disease biology, and public health to doctoral students, and is a member of the editorial board of several biomedical research journals. He is currently a member of the Virology-B study section of the NIH.

Dr. Gale is a recipient of the International Society for Interferon and Cytokine Research Milstein Award and the Ellison Medical Foundation New Scholar in Global Infectious Disease Research Award. He also received both the Burroughs Welcome Investigator in Infectious Disease Research Award and the Research Achievement Award from the W.M. Keck Foundation. He received his PhD in Pathobiology at the University of Washington's School of Public Health and Community Medicine.

K. George Chandy, Ph.D. - Scientific Advisor
Dr. Chandy is co-inventor of the ShK product family and has been the lead scientist responsible for its development and characterization. Dr. Chandy is an internationally recognized authority on mechanisms of autoimmunity and the roles of ion channels in cellular immunity. Working with scientific collaborators for two decades, Dr. Chandy discovered ion channels in T lymphocytes, and demonstrated their importance in immune cell proliferation. As co-discoverer of Kineta's key technological assets, a portfolio of Kv1.3 potassium channel blockers, his group used these blockers to define the physiological roles of potassium in immune development, inflammation and autoimmune diseases including multiple sclerosis, type 1 diabetes mellitus and rheumatoid arthritis.

Dr. Chandy received his medical degree from the University of Madras, India, and his PhD in Immunology from the University of Birmingham, England. He is Professor of Physiology & Biophysics, Microbiology & Molecular Genetics, and Medicine at the University of California, Irvine. He has been honored by the University with the prestigious Athalie Clark Research Achievement Award for excellence in research.

Jonathan Lakey, Ph.D. - Scientific Advisor
Dr. Lakey serves as a scientific advisor to Kineta's lead autoimmune program. Dr. Lakey has dedicated his medical career to the research and advancement of cell and tissue transplantation with a focus on diabetes and islet transplantation. His groundbreaking work at the University of Alberta led to the "Edmonton Protocol," a transplant treatment option for patients with type 1 diabetes. Working in partnership with Dr. James Shapiro and others, the team vastly improved islet isolation techniques and went on to successfully train more than 40 islet transplant centers worldwide to replicate the Edmonton Protocol.

Dr. Lakey has participated in numerous high level regulatory boards establishing the safety standards for cell and tissue transplantation in Canada. His research has received honors locally, nationally and internationally. Among his many scientific awards, he received the Meritorious Service Medal in 2005 from the Governor General of Canada.

Currently, Dr. Lakey serves as a Director of Research and Associate Professor of Surgery at the University of California, Irvine where he directs the clinical islet program. Dr. Lakey has earned multiple degrees from the University of Alberta: B.Sc, M.Sc and Ph.D. He did his post post-doctoral training in Indianapolis and Seattle.

Patrick Gearing, Ph.D. - Technical Operations
Dr. Gearing is a long-time member of the Kineta team, having led pharmaceutical manufacturing activities at our previous company, Illumigen Biosciences. He manages cGMP manufacturing and CMC regulatory affairs in support of the ShK-186 program, and more generally, technical operations at the company.

Dr. Gearing has more than 18 years experience as a protein chemist in the pharmaceutical industry. He has led process development, cGMP manufacturing, supply chain management, and quality auditing efforts for a number of developmental products. In addition, Dr. Gearing brings CRO contracts negotiation and project management experience to the team. Patrick has led product development efforts in the U.S., U.K., Europe, Australia, Japan, and Canada; he is experienced with the developmental regulatory environment in each of these countries.

Dr. Gearing is former Director of Pharmaceutical Development and Quality Systems at Seattle Genetics Inc. and a former Associate Director of Bioanalytical Development at Coulter Pharmaceuticals, South San Francisco, CA. Prior to this, Patrick held development positions at Protein Design Labs, Mountain View, CA, and at Immunex Corporation, Seattle, WA.

Dr. Gearing holds a Ph.D. and B.Sc. in Chemistry from Hariot-Watt University in Scotland.

Dan Burge, M.D. - Clinical Development
Dr. Burge directs Kineta's clinical strategy and clinical operations. Dr. Burge has been involved in the clinical development of investigational pharmaceutical products for the past 10 years and has managed Phase 1 - 4 clinical studies in multiple therapeutic areas with a primary focus on the autoimmune diseases.

Dr. Burge has successfully submitted numerous regulatory filings in the US and Europe including IND and sBLA filings and has participated in FDA advisory meeting presentations in support of new products. In addition, Dr. Burge played a major role in the preparation and submission of the original BLA for Enbrel® and has been responsible for pre- and post-marketing safety and surveillance programs for this and other products.

Dr. Burge is former Chief Medical Officer and Senior Vice-President at Trubion Pharmaceuticals, Seattle, WA, and former Vice-President at both Immunex and Amgen Corporations, where he was responsible for critical management functions within the clinical and regulatory arenas.

Board certified in Rheumatology and Internal Medicine, Dr. Burge spent 7 years as a practicing rheumatologist before entering the biotechnology industry. Dan is a member of the American College of Clinical Oncology and a Fellow Member of the American College of Rheumatology. He received his B.A. in Chemistry from Taylor University and his M.D. from the Jefferson Medical College in Philadelphia, PA.

Jeff Fellows - Regulatory Affairs
Mr. Fellows leads regulatory affairs at Kineta where he is responsible for developing and executing the regulatory strategy for ShK-186 and other company products.

His career in regulatory affairs spans more than 18 years and involves numerous filings in the U.S., Canada, Europe, Australia and Japan. His filing experience includes pre-IND, IND, CTA, BLA, and NDA regulatory submissions and Orphan Drug Applications. In addition, Jeff has led the regulatory and FDA product approval efforts for four approved pharmaceutical products: Neulasta®, Infergen®, Kineret®, and Sensipar®.

Throughout his career, Jeff has been involved in corporate global product strategy for early and late stage development compounds in the endocrine, inflammation, and neurology therapeutic areas and has led global regulatory teams focusing on worldwide product registration strategies. Formerly he served as Vice President of Regulatory Affairs at Cell Therapeutics Inc. in Seattle and Director of Regulatory Affairs and Global Regulatory Leader at Amgen Inc. in Thousand Oaks, CA.

Jeff has a B.S. in Microbiology from Oregon State University.

Eric W. Austin, Ph.D. - Nonclinical Development
Dr. Austin is a Senior Toxicology Consultant with Kineta, where he leads the company's nonclinical development strategy. He has more than 13 years of experience in preclinical drug development, ranging from lead optimization of drug candidates through IND/BLA filings and early clinical development.

Earlier he served as a toxicologist at ICOS Corp. where he was responsible for designing and implementing pre-GLP and GLP toxicology programs in support of IND and clinical development programs. He worked closely with product development teams and with representatives from clinical, CMC, quality control, chemistry, and regulatory affairs to advance drug candidates into the clinic. A significant amount of his time was also spent working with the ICOS business development group to evaluate potential in-licensing opportunities. He served as a toxicology expert in assessing potential licensing candidates.

Prior to ICOS, Dr. Austin also worked as a Study Director at Covance, where he directed GLP toxicity and safety pharmacology studies for a variety of indications with both small molecule and protein-based therapeutics with a particular emphasis on parenteral drugs. The development focus was novel NCEs for the treatment of cardiovascular disease, diabetes, and metabolic disorders.

Dr. Austin holds a Ph.D. in Pharmacology/Toxicology from Washington State University and is certified by the American Board of Toxicology.